Overview
Canada digital healthcare provider's Q1 revenue grew 25% yr/yr, driven by organic growth and acquisitions
Q1 adjusted EBITDA rose 56% yr/yr, with margin improving to 12%
Company reaffirmed 2026 guidance for revenue and adjusted EBITDA
Outlook
WELL Health reaffirms 2026 revenue guidance of C$1.55 bln to C$1.65 bln
Company expects 2026 adjusted EBITDA of C$175 mln to C$185 mln
WELL Canada targeting over C$800 mln in revenue and over C$100 mln in adjusted EBITDA within 12 months
Result Drivers
ORGANIC GROWTH AND ACQUISITIONS - Co said revenue and adjusted EBITDA growth were driven by organic expansion and acquisitions, including the addition of HEALWELL results
CANADIAN PATIENT SERVICES - Segment revenue and EBITDA growth were driven by acquisitions and 8% organic growth in Canadian Patient Services
PATIENT VISIT GROWTH - Total patient visits rose 17%, with Canadian visits up 33% yr/yr, driven by acquisitions and 13% organic growth
Company press release: ID:nNFC2LFyxG
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
C$0.06
Q1 Adjusted Gross Margin
44.30%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for WELL Health Technologies Corp is C$7.00, about 61.3% above its May 6 closing price of C$4.34
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 10 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)